aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
BioMarker Strategies, based in Baltimore, offers SnapPath, a live cell testing platform designed to enhance cancer treatment. The company's core mission is to improve the precision and effectiveness of cancer therapies through advanced diagnostic tools. Their market focus is on oncology, providing innovative solutions for personalized cancer care.
BioMarker Strategies has made significant strides in the field of cancer diagnostics with SnapPath, which allows for real-time testing of live tumor cells. This innovation has the potential to significantly impact treatment outcomes by enabling more tailored therapeutic approaches.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Cancer Treatment
Technology
Biotech
Tags
Healthtech
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
United States
When was BioMarker Strategies founded?
BioMarker Strategies was founded in 2006.
Where is BioMarker Strategies’s headquarters located?
BioMarker Strategies’s headquarters is located in Derwood, MD, US.
When was BioMarker Strategies’s last funding round?
BioMarker Strategies’s most recent funding round was for $525k (USD) in September 2016.
How many employees does BioMarker Strategies have?
BioMarker Strategies has 24 employees as of Feb 5, 2024.
How much has BioMarker Strategies raised to-date?
As of July 05, 2023, BioMarker Strategies has raised a total of $5.7M (USD) since Sep 6, 2016.
Add Comparison
Total Raised to Date
$5.7M
USD
Last Update Sep 6, 2016
Last Deal Details
$525k
USD
Sep 6, 2016
Series Unknown
Total Employees Over Time
24
As of Feb 2024
BioMarker Strategies Address
15601 Crabbs Branch Way
Derwood,
Maryland
20855
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts